WHIOCE PUBLISHING PTE. LTD.
PROVIDING
FIRST-CLASS SCIENTIFIC INFORMATION
FOR TOP SCHOLARS

2025 Volume 10, Issue 3
Journal of Medicines Development Sciences
ISSN: 2382-6371(Online) ISSN: 2382-6363(Print)

Research on the Interaction Mechanism of Molecular Signaling Pathways in Tumor Occurrence and Development in the Junction Area of Liver, Gallbladder, Pancreas and Spleen

Guodong Yu
Affiliated Hospital of Hebei University, Baoding 050031, Hebei, China

Copyright: © 2025 Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), permitting distribution and reproduction in any medium, provided the original work is cited.

Abstract: Tumors in the junction area of the liver, gallbladder, pancreas and spleen are complex and highly fatal malignant tumors. Due to their involvement in multiple organs such as the liver, gallbladder, pancreas and spleen, they have become a tumor-prone area. In recent years, advancements in molecular biology have promoted in-depth research on the occurrence and development of tumors in this region, especially the interactions of molecular signaling pathways. The occurrence and progression of tumors are the result of the combined action of multiple signaling pathways. This article reviews the main molecular signaling pathways and their interaction mechanisms in tumors at the junction of the liver, gallbladder, pancreas and spleen, explores their roles in the tumor microenvironment, drug resistance and metastasis, and looks forward to future clinical applications.

Keywords: Tumor in the junction area of liver, gallbladder, pancreas and spleen; Molecular signaling pathway; Tumorigenesis; Interaction mechanism; Tumor microenvironment

Online publication: September 26, 2025

1. Introduction

Tumors in the junction area of the liver, gallbladder, pancreas and spleen refer to malignant tumors that occur in the junction area of the liver, gallbladder, pancreas and spleen. These tumors have a high degree of malignancy due to their complex anatomical structure and multiple tissue components. With the development of modern molecular biology, the occurrence and development of tumors are no longer merely studied from the traditional anatomical and pathological perspectives, but are more focused on exploring the pathogenesis of tumors at the molecular level. Studies have shown that the occurrence of tumors in the junction area of the liver, gallbladder, pancreas and spleen is caused by the abnormal activation or inhibition of multiple molecular signaling pathways. These signaling pathways jointly promote the occurrence and progression of tumors through complex interactions. This article will explore the molecular signaling pathways and their interaction mechanisms of tumors in the junction area of the liver, gallbladder, pancreas and spleen, with the aim of providing new ideas and directions for the early diagnosis and treatment of tumors.

2. Characteristics and Distribution of Tumors in the Junction Area of the Liver, Gallbladder, Pancreas and Spleen

2.1. Anatomical features and clinical manifestations

The junction area of the liver, gallbladder, pancreas and spleen includes the liver, gallbladder, pancreas and spleen. These organs are closely adjacent anatomically and play a closely coordinated role in physiological functions. The liver, as the center of metabolism, plays a crucial role in tumorigenesis. The gallbladder stores and secretes bile and is one of the main sources of gallbladder cancer. The pancreas has important digestive and endocrine functions. The incidence of pancreatic cancer is increasing year by year, and the prognosis is poor. The spleen, as an immune organ, although tumors are relatively rare, the occurrence of tumors in it may affect the tumor development in the entire borderline region[1]. The clinical symptoms of tumors in the junction area of the liver, gallbladder, pancreas and spleen are usually manifested as abdominal pain, jaundice, weight loss, etc. However, these symptoms are relatively non-specific, making early diagnosis difficult and increasing the challenges of clinical treatment.

2.2. Tumor type

Tumor types in the junction area of the liver, gallbladder, pancreas and spleen include liver cancer, pancreatic cancer, gallbladder cancer and spleen tumors, etc. Liver cancer and pancreatic cancer are the most common tumor types in this region, and they are mostly discovered at an advanced stage, usually featuring strong malignant characteristics. Liver cancer is usually closely related to chronic liver diseases such as hepatitis and liver cirrhosis. The symptoms of pancreatic cancer are often not obvious, which leads to patients being diagnosed at an advanced stage by the time they are diagnosed. Although gallbladder cancer is relatively rare, it often occurs in the context of cholecystitis and gallstones, and the condition progresses rapidly[2]. Spleen tumors are generally benign, but in a few cases, they may also transform into malignant tumors. Overall, tumors in the junction area of the liver, gallbladder, pancreas and spleen mostly show malignant progression, and the early symptoms are not obvious, significantly increasing the difficulty of early intervention and the challenge of treatment.

2.3. Diagnosis and treatment of tumors

The early diagnosis of tumors in the junction area of the liver, gallbladder, pancreas and spleen faces huge challenges, mainly because the symptoms are often similar to those of other common diseases and lack specificity. Currently, diagnosis mainly relies on imaging examinations such as CT, MRI, and ultrasound, as well as histopathological examinations. These methods can help confirm the presence of tumors and classify them. With the advancement of molecular biology, genetic testing and molecular marker screening techniques have gradually been applied to the early diagnosis of tumors, especially showing promising prospects in the early detection of liver cancer and pancreatic cancer. In terms of treatment, tumors in the junction area of the liver, gallbladder, pancreas and spleen usually require a comprehensive treatment strategy, including surgical resection, radiotherapy, chemotherapy, targeted therapy, etc. In recent years, immune checkpoint inhibitors have achieved certain clinical results in the treatment of liver cancer and pancreatic cancer, showing a relatively positive prospect. However, the early diagnosis of tumors, personalized treatment and precision medicine remain the key research directions at present. In the future, it is necessary to continuously explore more efficient and precise treatment methods and early screening approaches[3].

3. The molecular mechanism of tumor occurrence and development in the junction area of the liver, gallbladder, pancreas and spleen

3.1. The main molecular signaling pathways

The occurrence of tumors in the junction area of the liver, gallbladder, pancreas and spleen is closely related to multiple signaling pathways, among which the most crucial ones include the Wnt/β-catenin pathway, PI3K/Akt/mTOR pathway, MAPK/ERK pathway and Notch pathway, etc. These signaling pathways play a significant role in the proliferation,

survival, migration and drug resistance formation of tumor cells.

Abnormal activation of the Wnt/β-catenin signaling pathway is commonly seen in the occurrence of liver cancer, promoting tumor proliferation and metastasis through nuclear translocation of β-catenin. The PI3K/Akt/mTOR pathway is common in pancreatic cancer and gallbladder cancer, which can promote cell survival and inhibit cell apoptosis. The MAPK/ERK pathway is activated in various tumor types, promoting cell proliferation and metastasis. The Notch signaling pathway also plays a significant role in the differentiation, proliferation and drug resistance of tumors.

3.2. The role in the tumor microenvironment

The tumor microenvironment plays a crucial role in the occurrence and development of tumors. Tumor cells interact with surrounding stromal cells, immune cells, vascular endothelial cells, etc., to form the microenvironment of the tumor. Studies have shown that in the microenvironment of tumors at the junction of the liver, gallbladder, pancreas and spleen, factors such as inflammatory response, hypoxia and immune escape all promote the occurrence and metastasis of tumors[4]. Tumor-related inflammatory responses not only promote tumor growth but also enhance the drug resistance of tumor cells to external treatments. The hypoxic state in the tumor microenvironment also activates multiple signaling pathways, further enhancing the invasiveness and metastasis ability of the tumor. The immune escape mechanism helps tumor cells evade clearance by the host immune system by altering the expression of surface antigens on tumor cells or by recruiting immunosuppressive cells. In addition, angiogenesis in tumors is also an important component of the tumor microenvironment, which supports the rapid growth and metastasis of tumors by providing nutrients and oxygen.

3.3. The mechanism of interaction among molecular signaling pathways

During the occurrence of tumors in the junction area of the liver, gallbladder, pancreas and spleen, multiple molecular signaling pathways do not act independently but interweave and interact with each other. Taking the PI3K/Akt/mTOR pathway and the Wnt/β-catenin pathway as examples, the activation of the PI3K/Akt/mTOR pathway can not only promote cell survival and proliferation, but also further activate the Wnt/β-catenin pathway by up-regulating the stability of β-catenin, thereby promoting tumor growth and metastasis. In addition, the activation of the MAPK/ERK pathway can also interact with the Notch signaling pathway through feedback mechanisms, enhancing the proliferation and invasiveness of tumor cells. The MAPK/ERK pathway can activate Notch receptors, thereby promoting drug resistance and proliferation of tumor cells, forming a vicious cycle[5]. The interaction of these signaling pathways enables tumor cells to evade normal growth control and cell cycle checkpoints, thereby promoting tumor progression and metastasis.

4. The role of molecular signaling pathways in tumor metastasis and drug resistance

4.1. The molecular mechanism of tumor metastasis

Tumor metastasis is one of the important factors leading to tumor-induced death, especially in tumors at the junction of the liver, gallbladder, pancreas and spleen. The metastasis of tumor cells is usually accompanied by abnormal activation of multiple signaling pathways. Studies have shown that the Wnt/β-catenin pathway, TGF-β pathway and PI3K/Akt pathway play a crucial role in the process of tumor metastasis. These pathways promote the invasion and metastasis of tumor cells by regulating their adhesion, motility and the degradation of extracellular matrix. The Wnt/β-catenin pathway promotes the metastasis of tumor cells from the primary site to distant sites by altering cell adhesion and motility[6]. TGF-β signaling promotes metastasis by regulating the epithelial-mesenchymal transition (EMT) process and enhancing the invasiveness of tumor cells. The PI3K/Akt pathway helps tumor cells degrade the matrix and cross it by enhancing the survival ability of tumor cells and promoting the secretion of matrix metalloproteinases, thereby facilitating the metastasis process.

4.2. The formation of tumor drug resistance

Tumor drug resistance is an important cause of chemotherapy failure and poor prognosis, especially in tumors at the

junction of the liver, gallbladder, pancreas and spleen. Drug resistance is usually closely related to changes in multiple molecular signaling pathways. For instance, the activation of the PI3K/Akt/mTOR pathway can enhance the survival ability of tumor cells and prevent apoptosis induced by chemotherapy drugs. The activation of the MAPK/ERK pathway promotes cell proliferation and slows down the killing effect of chemotherapy drugs, thereby making tumor cells resistant to the drugs. In addition, tumor cells further enhance their tolerance to drugs through mechanisms such as upregulating drug resistance genes and altering the ways drugs are taken up and excreted. Through in-depth research on drug resistance mechanisms, it is expected to discover new therapeutic targets to overcome these drug resistances.

4.3. Drug resistance treatment strategy

Targeted therapy and immunotherapy have provided new treatment directions for the drug resistance of tumors in the junction area of the liver, gallbladder, pancreas and spleen. Certain progress has been made in the development of drugs that target and inhibit signaling pathways such as the PI3K/Akt/mTOR pathway and the Wnt/β-catenin pathway. Targeting and inhibiting these pathways can effectively slow down the proliferation of tumor cells and enhance their sensitivity to chemotherapy drugs. In addition, the application of immune checkpoint inhibitors has achieved positive results in clinical treatment[7]. They can eliminate the immune escape of tumors, enhance the immune response of the body, and thereby overcome the drug resistance of tumors. In the future, combined treatment strategies may become an important means to deal with tumor drug resistance, especially in the face of tumor drug resistance mechanisms involving multiple signaling pathways.

5. Future research directions and clinical applications

5.1. The discovery of early diagnostic markers

With the continuous advancement of molecular biology techniques, the discovery of early diagnostic markers has become an important direction in the research of tumors at the junction of the liver, gallbladder, pancreas and spleen. By conducting in-depth analysis of the changes in tumor-related molecular signaling pathways and integrating high-throughput genomics, proteomics and metabolomics research, scientists are expected to screen out tumor markers with high specificity and sensitivity. These markers can help detect tumors at an early stage, especially in the early stage of tumors at the junction of the liver, gallbladder, pancreas and spleen, where the symptoms are not obvious and are easily overlooked. The discovery of early diagnostic markers will significantly enhance the early screening ability for tumors, thereby improving the prognosis of patients, enhancing treatment outcomes, and providing more precise diagnostic tools for clinical practice[8].

5.2. The development of targeted therapy

Targeted therapy, as one of the important means for treating tumors in the junction area of the liver, gallbladder, pancreas and spleen, will continue to play a key role in the future. By precisely targeting the key molecular signaling pathways in tumor cells, targeted therapy can selectively inhibit the proliferation and growth of tumor cells, avoid damage to normal cells, thereby enhancing the therapeutic effect and reducing side effects[9]. Future research will focus on developing new targeted drugs, especially those for difficult-to-treat types such as liver cancer and pancreatic cancer. Exploring the interactions among different signaling pathways and combining them with individualized treatment will provide more effective therapeutic strategies for the precise treatment of tumors in the junction area of the liver, gallbladder, pancreas and spleen, and promote the development of targeted therapy.

5.3. The application of immunotherapy

Immunotherapy, as a breakthrough in the field of cancer treatment in recent years, has broad application prospects in tumors at the junction of the liver, gallbladder, pancreas and spleen. Tumor cells evade the recognition and attack of the immune system through multiple mechanisms[10]. Therefore, research on the immune escape mechanisms of tumors is

of vital importance. By developing new immunotherapy strategies, such as immune checkpoint inhibitors, CAR-T cell therapy, and tumor vaccines, the immune response of the body can be effectively enhanced, thereby changing the treatment pattern of tumors in the junction area of the liver, gallbladder, pancreas and spleen. Future research will focus on enhancing the effectiveness of immunotherapy, overcoming the side effects and drug resistance issues related to immunotherapy, providing more targeted and personalized treatment plans for clinical practice, and further improving the treatment outcome.

6. Conclusion

The occurrence and development of tumors in the junction area of the liver, gallbladder, pancreas and spleen is a complex process involving the interaction of multiple molecular signaling pathways. In-depth research on the interaction mechanisms of these signaling pathways can help us better understand the occurrence and development of tumors, providing new theoretical basis and clinical strategies for the early diagnosis and treatment of tumors. In the future, with the continuous advancement of molecular biology techniques, the diagnosis and treatment of tumors in the junction area of the liver, gallbladder, pancreas and spleen will enter a new stage.

Disclosure statement

The author declares no conflict of interest.

References

[1] Yin P, Yang J, 2024, The application progress and current situation of membrane Anatomy in Hepatobiliary, Pancreatic and splenic surgery. Chinese and Foreign Medical Sciences, 43(36):195-198.

[2] Song H Y, Ding R F, Ji Q F, 2024, Retrospective Analysis of the Impact of Standardized Surgical Nursing Cooperation on Patients converting from robot to open Surgery in Hepatobiliary, Pancreatic and splenic Surgery. Shanghai Nursing Association. Compilation of Papers from the 6th Shanghai International Nursing Conference (Part 2). Shanghai Changhai Hospital, 343.

[3] Yin H, 2024, Hepatobiliary, Pancreatic and Splenic Surgery Team of the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) Changhai has a four-step battle against the “King of Cancer”. Doctor’s Journal, (A07).

[4] Guo H, 2024, Practice and Prospect of Big Data Technology in Postoperative Care of Patients in Hepatobiliary Surgery: A Review of “Nursing in Hepatobiliary and Pancreatic Surgery”. Contemporary Chemical Engineering, 53(07):1765.

[5] Ma H, 2024, The Application Value of Magnetic Nursing Management Based on the Current Situation - Background - Assessment - Recommendation Communication Model Implemented by Nursing Staff in Hepatobiliary Surgery. Primary Medicine Forum, 28(20):1-3+15.

[6] Li J W, Zhao K F, Wu G, 2024, Clinical application progress of single-port laparoscopic surgery in the treatment of liver, gallbladder, pancreas and spleen diseases. Journal of Laparoscopic Surgery, 29(07):538-540+545.

[7] Liu H, Wang Y Y, Qian Y B, 2024, Analysis of the Effect of Clinical Pharmacists’ Participation in Nutritional Assessment and Intervention in the Treatment of Patients with Hepatobiliary and Pancreatic Malignancies. Chinese Journal of Hospital Pharmacy, 44(17):2038-2043.

[8] Mo J H, Wei Q, Pang Q X, 2024, Application of 3D Model Reconstruction Technology Combined with Mind Mapping in Clinical Teaching of Hepatobiliary and Pancreatic Surgery Nursing. Minimally invasive Medicine, 19(03):335-339.

[9] Feng D, Ge L, 2024, Analysis of the Application Effect of Case Teaching in Hepatobiliary Surgery Nursing Teaching. Yulin

Medical Association. Proceedings of the Fifth National Medical Research Forum (Part II). Department of Hepatobiliary, Pancreatic and Spleen Surgery, Affiliated Hospital of Inner Mongolia Medical University, B District, 123-128.

[10] Zhao H P, 2020, “Grassland Talent” Innovation Team - Liver, Gallbladder, Pancreas and Spleen Tumor and Minimally Invasive Surgery Innovation Team. Inner Mongolia Medical University Affiliated Hospital, Inner Mongolia Autonomous Region.

Publisher’s note

Whioce Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.